The published work is a Phase I/Ib clinical trial titled: Phase I/Ib study evaluating safety, efficacy, pharmacokinetics and pharmacodynamics of NIZ985 monotherapy and in combination with an anti-PD-1 agent in patients with advanced solid tumors or lymphoma. The title indicates the trial evaluated multiple early-phase endpoints: safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) for both monotherapy and combination regimens.
The article lists a multi-institutional authorship led by Elena Garralda and includes Patrick Schöffski, Arjun Oberoi, Martin Schuler, Heike Richly, Paolo A. Ascierto and many others. Contributing institutions span Europe, North America and Asia, including:
Author contact information for the corresponding author (Elena Garralda) is provided in the PubMed entry (electronic address egarralda@vhio.net).
The citation details in the PubMed entry are:
The PubMed record classifies the article as a Clinical Trial. A full text link is indicated via Elsevier Science in the PubMed record.
The trial title explicitly identifies the principal objectives as evaluation of safety, efficacy, pharmacokinetics and pharmacodynamics of NIZ985 both as monotherapy and in combination with an anti-PD-1 immune checkpoint inhibitor. These objectives reflect a comprehensive early-phase assessment intended to characterize tolerability, preliminary antitumor activity and PK/PD behavior.
The study population, as given in the PubMed title, comprises patients with advanced solid tumors or lymphoma. No additional demographic, staging, histology-specific or prior-treatment eligibility criteria are reported in the supplied source excerpt.
The PubMed entry provided here contains bibliographic metadata, author and affiliation listings, and the article title. However, the following essential trial details were not present in the supplied excerpt and therefore are not reported here:
Because these items are not available in the provided PubMed excerpt, they cannot be inferred or summarized here.
The PubMed record provides the DOI (10.1016/j.ejca.2026.116899) and a full text link via Elsevier Science. Clinicians, trialists and other readers seeking complete methodology, participant numbers, dosing, safety, efficacy, PK/PD results and the authors' interpretation should consult the full text of the article in European Journal of Cancer or access the record through PubMed using PMID 42407248. The PubMed entry indicates the publication is categorized as a Clinical Trial, and the full manuscript will be required to obtain the missing trial-specific data that are not present in this excerpt.